These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

252 related articles for article (PubMed ID: 9365196)

  • 1. Clinical use of aromatase inhibitors in the treatment of advanced breast cancer.
    Trunet PF; Vreeland F; Royce C; Chaudri HA; Cooper J; Bhatnagar AS
    J Steroid Biochem Mol Biol; 1997 Apr; 61(3-6):241-5. PubMed ID: 9365196
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecular Action and Clinical Relevance of Aromatase Inhibitors.
    Murphy MJ
    Oncologist; 1998; 3(2):129-130. PubMed ID: 10388095
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Approval summary: letrozole in the treatment of postmenopausal women with advanced breast cancer.
    Cohen MH; Johnson JR; Li N; Chen G; Pazdur R
    Clin Cancer Res; 2002 Mar; 8(3):665-9. PubMed ID: 11895893
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Are all aromatase inhibitors the same? A review of controlled clinical trials in breast cancer.
    Berry J
    Clin Ther; 2005 Nov; 27(11):1671-84. PubMed ID: 16368441
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Extended breast cancer treatment with an aromatase inhibitor (Letrozole) after tamoxifen: why, who and how long?
    Kaufmann M; Rody A
    Eur J Obstet Gynecol Reprod Biol; 2006 Jun; 126(2):146-54. PubMed ID: 16621229
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Current status and prospectives of aromatase inhibitors in the treatment of advanced breast cancer].
    Boccardo F
    Minerva Ginecol; 1998 Mar; 50(3):51-63. PubMed ID: 9595916
    [TBL] [Abstract][Full Text] [Related]  

  • 7. New aromatase inhibitors as second-line endocrine therapy in postmenopausal patients with metastatic breast carcinoma: a pooled analysis of the randomized trials.
    Carlini P; Bria E; Giannarelli D; Ferretti G; Felici A; Papaldo P; Fabi A; Nisticò C; Di Cosimo S; Ruggeri EM; Milella M; Mottolese M; Terzoli E; Cognetti F
    Cancer; 2005 Oct; 104(7):1335-42. PubMed ID: 16088965
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Are all aromatase inhibitors the same? A review of the current evidence.
    Jänicke F
    Breast; 2004 Dec; 13 Suppl 1():S10-8. PubMed ID: 15585378
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Aromatase inhibitors in breast cancer therapy.
    Brueggemeier RW
    Expert Rev Anticancer Ther; 2002 Apr; 2(2):181-91. PubMed ID: 12113240
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The estrogen suppression after sequential treatment with formestane in advanced breast cancer patients.
    Zilembo N; Bajetta E; Bichisao E; Martinetti A; La Torre I; Bidoli P; Longarini R; Portale T; Seregni E; Bombardieri E
    Biomed Pharmacother; 2004 May; 58(4):255-9. PubMed ID: 15183852
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The impact of hormone receptor status on the clinical efficacy of the new-generation aromatase inhibitors: a review of data from first-line metastatic disease trials in postmenopausal women.
    Buzdar AU; Vergote I; Sainsbury R
    Breast J; 2004; 10(3):211-7. PubMed ID: 15125747
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Are aromatase inhibitors superior to antiestrogens?
    Howell A; Buzdar A
    J Steroid Biochem Mol Biol; 2005 Feb; 93(2-5):237-47. PubMed ID: 15860266
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Aromatase inhibitors: new endocrine treatment of breast cancer.
    Brueggemeier RW
    Semin Reprod Med; 2004 Feb; 22(1):31-43. PubMed ID: 15083379
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The role of tamoxifen and aromatase inhibitors/inactivators in postmenopausal patients.
    Pritchard KI
    Clin Cancer Res; 2001 Dec; 7(12 Suppl):4356s-4359s; discussion 4411s-4412s. PubMed ID: 11916225
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The role of aromatase inhibitors as adjuvant therapy for early breast cancer in postmenopausal women.
    Mouridsen HT; Robert NJ
    Eur J Cancer; 2005 Aug; 41(12):1678-89. PubMed ID: 16098456
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Endocrine manipulation in advanced breast cancer: recent advances with SERM therapies.
    Johnston SR
    Clin Cancer Res; 2001 Dec; 7(12 Suppl):4376s-4387s; discussion 4411s-4412s. PubMed ID: 11916228
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Aromatase inhibitors in the management of early breast cancer.
    Nabholtz JM
    Eur J Surg Oncol; 2008 Nov; 34(11):1199-207. PubMed ID: 18359182
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Where do selective estrogen receptor modulators (SERMs) and aromatase inhibitors (AIs) now fit into breast cancer treatment algorithms?
    Howell A; Howell SJ; Clarke R; Anderson E
    J Steroid Biochem Mol Biol; 2001 Dec; 79(1-5):227-37. PubMed ID: 11850229
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Aromatase inhibitors and breast cancer.
    Brodie AM; Njar VC
    Semin Oncol; 1996 Aug; 23(4 Suppl 9):10-20. PubMed ID: 8824460
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Aromatase inhibitors for treatment of advanced breast cancer in postmenopausal women.
    Gibson LJ; Dawson C; Lawrence DH; Bliss JM
    Cochrane Database Syst Rev; 2007 Jan; (1):CD003370. PubMed ID: 17253488
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.